Roslin Cells Relocates to the Scottish Centre for Regenerative Medicine
Wednesday, November 23, 2011 at 9:00AM
Roslin Cells

Edinburgh, Scotland – 23 November 2011: Roslin Cells Ltd., world leaders in the isolation of new clinical grade pluripotent stem cells, announced today that it has now moved to the new Scottish Centre for Regenerative Medicine at Edinburgh BioQuarter. 

This is a major watershed in the Company’s development, enabling it to co-locate with University of Edinburgh’s MRC Centre for Regenerative Medicine and to operate the SCRM’s 1,000 sq m GMP cell processing facility in conjunction with the Scottish National Blood Transfusion Service. 

The GMP facility is quite simply the state of the art for cell therapy manufacture in Europe.  With seven clean rooms as well as associated quality control laboratories, it will enable Roslin Cells to play a leading role in the translation of stem cell biology to new cell therapies.  In the coming months, the Company’s development programme will expand rapidly to encompass the wide variety of cell types being used in cell therapy and to build on the Company’s collaborations with the UK science base and, in particular, the world leading research underway at the MRC Centre for Regenerative Medicine.

Aidan Courtney, Roslin Cells CEO said: “The smooth transfer of our operation to the SCRM was the result of an immense effort by my colleagues at Roslin Cells for which I am extremely grateful.  While 2011 has been a year of transition and hard graft, I am confident that 2012 will be the first of many that deliver tangible results for the investment made and the foresight of those who initiated the creation of Edinburgh BioQuarter and the SCRM.”

 

About Roslin Cells

Roslin Cells Ltd was established as an independent company by Roslin Institute in 2006 with the aim of providing ethically sourced, pluripotent human cells manufactured to the highest quality available according to Good Manufacturing Practice (GMP standards). This level of quality is critical to their intended use in therapeutic applications.  The Company now also assists academic and commercial organisations to translate fundamental research into GMP compliant processes which can be used in the production of cell therapies.  In October 2010 the Company announced its Cell Therapy Partner Program through which it helps the development of new cell therapies.

Roslin Cells is headquartered in Edinburgh, Scotland, and is a not for profit organisation.

-ends-

For more information please contact Aidan Courtney, Chief Executive Officer

Phone + 44 (0)131 651 9610; Email: a.courtney@roslincells.com;

www.roslincells.com

Article originally appeared on Roslin Cells (http://roslincells.com/).
See website for complete article licensing information.